Oklo stock tumbles as Financial Times scrutinizes valuation
Jason Drew Smith, General Counsel at UroGen Pharma Ltd (NASDAQ:URGN), a biopharmaceutical company with impressive gross profit margins of 88.5%, sold 1,520 shares of the company’s ordinary shares at $19.11 on September 8th, 2025. The sale comes as the stock trades near its 52-week high of $21.71, having gained over 110% in the past six months. InvestingPro subscribers can access 12 additional key insights about URGN’s performance. The total value of the sale was $29,047.
On September 7th, Smith also exercised options on 3,333 shares of Restricted Stock Units, which had a value of $0. Following these transactions, Smith directly owns 43,305 shares of UroGen Pharma Ltd.
In other recent news, UroGen Pharma has been the focus of several significant developments. The company reported its second-quarter 2025 financial results, revealing revenue of $24.2 million, which was below H.C. Wainwright’s forecast of $25.9 million. Despite this, JELMYTO, a treatment for upper tract urothelial carcinoma, experienced an 11% increase in revenue compared to the previous year. Analysts have been actively assessing UroGen’s potential, with Piper Sandler initiating coverage with an Overweight rating, citing confidence in the Zusduri launch. TD Cowen reiterated a Buy rating and a $35 price target, noting that the Zusduri launch is exceeding expectations with numerous treatment sites activated. H.C. Wainwright adjusted its price target to $40 from $50 while maintaining a Buy rating, reflecting on the recent earnings report. Guggenheim raised its price target to $32, highlighting the strategic importance of the Zusduri launch. Additionally, UroGen Pharma’s shareholders approved the election of seven directors and other proposals at the company’s 2025 Annual Meeting.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.